Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction.

× No keyword cloud information.

13 in total

1. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease.

Authors: P W Lowry; C L Franklin; A L Weaver; M G Pike; D C Mays; W J Tremaine; J J Lipsky; W J Sandborn
Journal: Gut Date: 2001-11 Impact factor: 23.059

2. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.

Authors: Gabriele Stocco; Eva Cuzzoni; Sara De Iudicibus; Diego Favretto; Noelia Malusà; Stefano Martelossi; Elena Pozzi; Paolo Lionetti; Alessandro Ventura; Giuliana Decorti
Journal: World J Gastroenterol Date: 2015-03-28 Impact factor: 5.742

Review 3. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors: Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal: Clin Pharmacokinet Date: 2018-09 Impact factor: 6.447

Review 4. The thiopurines: an update.

Authors: Sally Coulthard; Linda Hogarth
Journal: Invest New Drugs Date: 2005-12 Impact factor: 3.850

Review 5. Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

Authors: M Schwab; U Klotz
Journal: Clin Pharmacokinet Date: 2001 Impact factor: 6.447

6. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.

Authors: P W Lowry; C L Franklin; A L Weaver; C L Szumlanski; D C Mays; E V Loftus; W J Tremaine; J J Lipsky; R M Weinshilboum; W J Sandborn
Journal: Gut Date: 2001-11 Impact factor: 23.059

Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction.

1. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease.

2. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.

Review 3. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Review 4. The thiopurines: an update.

Review 5. Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

6. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.

7. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease.

8. TPMT in the treatment of Crohn's disease with azathioprine.

Review 9. Comparative tolerability of therapies for ulcerative colitis.

Review 10. Optimizing immunomodulator therapy for inflammatory bowel disease.